Gene:
NGF
nerve growth factor (beta polypeptide)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all NGF variant annotations

Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs2239622 -136-1338T>C, 115837709A>G, 48149T>C, 85809627A>G
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142

Overview

Alternate Names:  NGFB
Alternate Symbols:  None
PharmGKB Accession Id: PA162397475

Details

Cytogenetic Location: chr1 : p13.1 - p13.2
GP mRNA Boundary: chr1 : 115828537 - 115880857
GP Gene Boundary: chr1 : 115825537 - 115890857
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. ARMS-mediated activation - (Reactome via Pathway Interaction Database)
  2. Axonal growth stimulation - (Reactome via Pathway Interaction Database)
  3. Ceramide signalling - (Reactome via Pathway Interaction Database)
  4. erk1/erk2 mapk signaling pathway - (BioCarta via Pathway Interaction Database)
  5. Frs2-mediated activation - (Reactome via Pathway Interaction Database)
  6. nerve growth factor pathway (ngf) - (BioCarta via Pathway Interaction Database)
  7. Neurotrophic factor-mediated Trk receptor signaling - (Pathway Interaction Database NCI-Nature Curated)
  8. NFG and proNGF binds to p75NTR - (Reactome via Pathway Interaction Database)
  9. NGF processing - (Reactome via Pathway Interaction Database)
  10. p75(NTR)-mediated signaling - (Pathway Interaction Database NCI-Nature Curated)
  11. p75NTR negatively regulates cell cycle via SC1 - (Reactome via Pathway Interaction Database)
  12. phosphorylation of mek1 by cdk5/p35 down regulates the map kinase pathway - (BioCarta via Pathway Interaction Database)
  13. PI3K/AKT signalling - (Reactome via Pathway Interaction Database)
  14. PLC-gamma1 signalling - (Reactome via Pathway Interaction Database)
  15. Retrograde neurotrophin signalling - (Reactome via Pathway Interaction Database)
  16. role of erk5 in neuronal survival pathway - (BioCarta via Pathway Interaction Database)
  17. Signalling to p38 via RIT and RIN - (Reactome via Pathway Interaction Database)
  18. Signalling to RAS - (Reactome via Pathway Interaction Database)
  19. Signalling to STAT3 - (Reactome via Pathway Interaction Database)
  20. Trk receptor signaling mediated by PI3K and PLC-gamma - (Pathway Interaction Database NCI-Nature Curated)
  21. TRKA activation by NGF - (Reactome via Pathway Interaction Database)
  22. trka receptor signaling pathway - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
methadone

Curated Information ?

Publications related to NGF: 4

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target. Indian journal of dermatology. 2014. Raychaudhuri Smriti K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013. Levran Orna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Nerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. The pharmacogenomics journal. 2011. Levran O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
100 years and counting: prospects for defeating Alzheimer's disease. Science (New York, N.Y.). 2006. Roberson Erik D, et al. PubMed

LinkOuts

Entrez Gene:
4803
OMIM:
162030
608654
RefSeq RNA:
NM_002506
RefSeq Protein:
NP_002497
ALFRED:
LO040475U
ModBase:
P01138
HumanCyc Gene:
HS05847
HGNC:
7808

Common Searches